Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA
This article was originally published in The Tan Sheet
Executive Summary
Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.
You may also be interested in...
First-In-Class PreHistin Could Challenge Antihistamines In Two Years – Exec
Irvine, Calif.-based Cobalis, which has patent for using cyanocobalamin to treat Immunoglobulin E-mediated allergic diseases, expects NDA submission in Q3 2007.
First-In-Class PreHistin Could Challenge Antihistamines In Two Years – Exec
Irvine, Calif.-based Cobalis, which has patent for using cyanocobalamin to treat Immunoglobulin E-mediated allergic diseases, expects NDA submission in Q3 2007.
First-In-Class PreHistin Could Challenge Antihistamines In Two Years – Exec
Specialty pharmaceutical firm Cobalis expects its over-the-counter "pre-histamine" allergy treatment would be a first-in-class product if it becomes available as planned in 2008